LIFE SAVING DRUGS PROGRAM EXPERT PANEL

19th MEETING: 13 December 2024 AGENDA

1. Standing business
   1. Welcome, apologies and Conflicts of Interest
   2. Update on actions from previous meetings
   3. Correspondence
   4. Report from the secretariat
2. 24 month review of existing LSDP medicines
   1. Avalglucosidase alfa (Nexviazyme®) – for the treatment of Pompe disease
3. Applications for new LSDP medicines
   1. Olipudase alfa (Xenpozyme®) – for the treatment of acid sphingomyelinase deficiency (ASMD) types A/B and B
4. Other business
   1. Enhance HTA report